BridgeBio Pharma’s approval of Beyonttra comes three months after the drug landed FDA approval for cardiomyopathy caused by transthyretin amyloidosis. Our recap of recent regulatory news also spans approvals in cancer, immunology, vaccines, and more. The post On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval appeared first on MedCity…
The life expectancy among Native Americans in the western United States has dropped below 64 years, close to life expectancies in the Democratic Republic of the Congo and Haiti. For many Asian Americans, it’s around 84 — on par with life expectancies in Japan and Switzerland. Americans’ health has long been unequal, but a new…
Breast cancer survivor Kate Dilligan is the CEO of Cooler Heads, a company that sells a portable and self-administered scalp cooling device. The system helps chemotherapy patients retain their hair, as therefore their self-esteem and privacy. The post ‘It’s Not About Beauty, It’s About Privacy’: How One Cancer Survivor Is Changing Chemo Care appeared first…
An Alto drug candidate for major depressive disorder failed to meet primary and secondary goals of a placebo-controlled Phase 2b test. The disappointing result could stymie plans for further tests of the small molecule in PTSD and bipolar depression. The post Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral appeared first on MedCity…
Most employers have little idea what the pharmacy benefit managers they hire do with the money they exchange for the medications used by their employees, according to a KFF survey released Wednesday morning. In KFF’s latest employer health benefits survey, company officials were asked how much of the rebates collected from drugmakers by pharmacy benefit…
Joey Ballard is an internal medicine resident at the University of Illinois-Chicago. He wrote to “An Arm and a Leg” about a resolution the American Medical Association recently adopted calling on hospitals to do more to make sure patients who qualify for charity care get it. And that legislators and regulators make sure that’s happening….
“Taking away opportunities to get covered is not the way to eliminate fraud,” Young Invincibles’ director says
Kaiser Permanente Ventures, Texas Medical Center Venture Fund, Yale New Haven Health join General Catalyst in $10.5 million funding round
Health systems preparing for an M&A, or even those not immediately considering one, must prioritize a robust workforce data strategy. This approach is essential for navigating today’s increasingly frequent healthcare consolidations. The post Prioritize Provider Data for Seamless M&A Success appeared first on MedCity News.
Blood centers are neutral partners, as they do not compete with hospitals for patients. Instead, they complement hospitals by providing a focused array of high-quality, specialized, patient-centric services, allowing hospitals to maintain primary relationships with patients and their families. The post Blood Centers Complement Hospitals to Drive Cell and Gene Therapy Access appeared first on…